Deberdt W
UCB Pharma, Chemin du Foriest, Braine-l'Alleud, Belgium.
Life Sci. 1994;55(25-26):2057-66. doi: 10.1016/0024-3205(94)00386-6.
In contrast to other kinds of psychotropic drugs, nootropics or cognition enhancing drugs may be indicated, not for the direct treatment of the pathology itself, but for improving or restoring the remaining brain functions. Brain functions are normally trained during various kinds of non-medical therapy, such as physiotherapy, speech therapy, occupational therapy, memory training etc... In research little attention has been paid to the combination of both kinds of therapeutic approaches, probably because of the important methodological difficulties. This combination however, offers various interesting perspectives: L. ISRAEL examined in two placebo-controlled studies the effects of either 160 mg/d of ginkgo biloba extractum (GBE) or piracetam 2.4 or 4.8 g/d, combined with a memory training program, in nondemented patients complaining of memory problems. The results of both studies suggest that nootropic drug treatment and memory training have each an effect on different cognitive functions and, hence, are complementary. Some functions, like attention/perception in the GBE study and learning in the piracetam study, seem to benefit from both treatments, suggesting a mutually potentiating effect of drug treatment and training. This potentiation is very clear in the treatment of dyslexic children: in a placebo-controlled study piracetam 3.3 g/d, in combination with normal school teaching and more specific logopedic therapy, allowed a normal progression during the full school year in reading accuracy and reading comprehension, while the placebo treated children getting a similar training progressed only with 50%. Recently promising results were obtained in the treatment of dysphasic patients with a combination of speech therapy and piracetam 4.8 g/d, especially when given during the first months after the stroke, or otherwise in combination with an intensive speech training. In both double-blind studies the piracetam treated group improved about 60% more than the group who only got speech therapy and placebo. All these data may be explained by the restorative or enhancing influence of nootropic drugs on neurotransmitter systems closely related to learning and memory functions. E.g. piracetam restores the availability and function of muscarinic and NMDA receptors in aging animals, most probably through a modulation of the psychico-chemical properties of the neuronal membrane such as the membrane fluidity.
与其他类型的精神药物不同,促智药或认知增强药物的使用指征可能并非直接治疗病理本身,而是用于改善或恢复剩余的脑功能。脑功能通常在各种非药物治疗过程中得到训练,如物理治疗、言语治疗、职业治疗、记忆训练等……在研究中,很少有人关注这两种治疗方法的结合,这可能是由于存在重大的方法学困难。然而,这种结合提供了各种有趣的前景:L. 伊斯雷尔在两项安慰剂对照研究中,考察了每天160毫克银杏叶提取物(GBE)或2.4克或4.8克吡拉西坦与记忆训练计划相结合,对抱怨有记忆问题的非痴呆患者的影响。两项研究的结果表明,促智药物治疗和记忆训练对不同的认知功能各有影响,因此具有互补性。某些功能,如GBE研究中的注意力/感知和吡拉西坦研究中的学习,似乎从两种治疗中均受益,这表明药物治疗和训练具有相互增强的作用。这种增强作用在阅读障碍儿童的治疗中非常明显:在一项安慰剂对照研究中,每天3.3克吡拉西坦与正常学校教学及更具针对性的言语治疗相结合,使得阅读准确性和阅读理解在整个学年中能够正常进步,而接受类似训练的安慰剂治疗儿童仅进步了50%。最近,在言语治疗与每天4.8克吡拉西坦联合治疗失语症患者方面取得了有前景的结果,尤其是在中风后的头几个月给药,或者与强化言语训练相结合时。在两项双盲研究中,吡拉西坦治疗组比仅接受言语治疗和安慰剂的组改善程度高出约60%。所有这些数据都可以通过促智药物对与学习和记忆功能密切相关的神经递质系统的恢复或增强作用来解释。例如,吡拉西坦可恢复衰老动物中毒蕈碱和NMDA受体的可用性和功能,很可能是通过调节神经元膜的心理化学性质,如膜流动性来实现的。